AR125920A2 - Composiciones que comprenden vortioxetina y donepezil - Google Patents

Composiciones que comprenden vortioxetina y donepezil

Info

Publication number
AR125920A2
AR125920A2 ARP220101337A ARP220101337A AR125920A2 AR 125920 A2 AR125920 A2 AR 125920A2 AR P220101337 A ARP220101337 A AR P220101337A AR P220101337 A ARP220101337 A AR P220101337A AR 125920 A2 AR125920 A2 AR 125920A2
Authority
AR
Argentina
Prior art keywords
compositions
vortioxetine
donepezil
treatment
cognitive dysfunctions
Prior art date
Application number
ARP220101337A
Other languages
English (en)
Inventor
Morillo Connie Snchez
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR125920A2 publication Critical patent/AR125920A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proveen composiciones farmacéuticas que comprenden vortioxetina y donepezil, y el uso de dichas composiciones para el tratamiento de disfunciones cognitivas.
ARP220101337A 2012-12-13 2022-05-19 Composiciones que comprenden vortioxetina y donepezil AR125920A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261736799P 2012-12-13 2012-12-13

Publications (1)

Publication Number Publication Date
AR125920A2 true AR125920A2 (es) 2023-08-23

Family

ID=49943326

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP130104651A AR093939A1 (es) 2012-12-13 2013-12-12 Composiciones que comprenden vortioxetina y donepezil
ARP220101337A AR125920A2 (es) 2012-12-13 2022-05-19 Composiciones que comprenden vortioxetina y donepezil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP130104651A AR093939A1 (es) 2012-12-13 2013-12-12 Composiciones que comprenden vortioxetina y donepezil

Country Status (44)

Country Link
US (1) US9211288B2 (es)
EP (1) EP2931276B1 (es)
JP (1) JP6257641B2 (es)
KR (1) KR102171152B1 (es)
CN (1) CN104853755B (es)
AP (1) AP2015008498A0 (es)
AR (2) AR093939A1 (es)
AU (1) AU2013357308B2 (es)
BR (1) BR112015013675B1 (es)
CA (1) CA2893468C (es)
CL (1) CL2015001615A1 (es)
CR (1) CR20150303A (es)
CY (1) CY1120098T1 (es)
DK (1) DK2931276T3 (es)
DO (1) DOP2015000133A (es)
EA (1) EA028300B1 (es)
EC (1) ECSP15023182A (es)
ES (1) ES2663680T3 (es)
GE (1) GEP201706739B (es)
GT (1) GT201500143A (es)
HK (1) HK1212601A1 (es)
HR (1) HRP20180333T1 (es)
HU (1) HUE036280T2 (es)
IL (1) IL239192B (es)
LT (1) LT2931276T (es)
MA (1) MA38253B1 (es)
ME (1) ME03029B (es)
MX (1) MX362886B (es)
MY (1) MY171802A (es)
NI (1) NI201500078A (es)
NO (1) NO2970700T3 (es)
NZ (1) NZ708595A (es)
PE (1) PE20151026A1 (es)
PH (1) PH12015501302B1 (es)
PL (1) PL2931276T3 (es)
PT (1) PT2931276T (es)
RS (1) RS56949B1 (es)
RU (1) RU2635528C2 (es)
SG (1) SG11201504483YA (es)
SI (1) SI2931276T1 (es)
TN (1) TN2015000235A1 (es)
UA (1) UA114016C2 (es)
WO (1) WO2014090929A1 (es)
ZA (1) ZA201504274B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218482B (zh) * 2014-06-24 2018-04-06 杭州和泽医药科技有限公司 沃替西汀氢溴酸盐β晶型的制备方法
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
CN105315184B (zh) * 2015-06-26 2017-03-29 上海医药工业研究院 一种沃替西汀的制备方法及其中间体
AU2016296205B2 (en) * 2015-07-17 2021-11-11 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
CN105534933A (zh) * 2016-01-19 2016-05-04 美吉斯制药（厦门）有限公司 一种沃替西汀口腔崩解片及其制备方法
SG11201810644TA (en) 2016-07-01 2018-12-28 H Lundbeck As Vortioxetine dosing regimes for fast onset of antidepressant effect
EP3915564A1 (en) * 2017-03-30 2021-12-01 Rundle Research, LLC Vortioxetine and mao inhibitors for treating depression
US10398691B2 (en) 2017-03-30 2019-09-03 Rundle Research, LLC Methods of treating depression

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK569087A (da) 1986-10-31 1988-05-01 Sumitomo Pharma Quinolin-derivater, deres fremstilling og anvendelse
IT1225462B (it) 1987-04-03 1990-11-14 Mediolanum Farmaceutici Srl Sali organici di derivati della fisostigmina
DE3856594D1 (de) 1987-05-04 2008-11-27 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
EP0403713A1 (en) 1989-06-22 1990-12-27 Merrell Dow Pharmaceuticals Inc. Novel acetylcholinesterase inhibitors
US4914102A (en) 1989-09-28 1990-04-03 Hoechst Roussel Pharmaceuticals, Inc. N-aminocarbamates related to physostigmine, pharmacentical compositions and use
TW200462B (es) 1990-09-27 1993-02-21 Hoechst Roussel Pharma
US5246947A (en) 1991-09-23 1993-09-21 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
US5231093A (en) 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
ES2042384B1 (es) 1991-12-26 1994-06-01 Boehringer Ingelheim Espana Procedimiento para obtener derivados bis-piridinicos.
SE9302080D0 (sv) 1993-06-16 1993-06-16 Ab Astra New compounds
IL126308A0 (en) 1996-04-12 1999-05-09 Hoechst Marion Roussel Inc Isatin derivatives as acetylcholinesterase inhibitors and analgesics
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP4405811B2 (ja) 2002-03-29 2010-01-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 （１−インダノン）−（１，２，３，６−テトラヒドロピリジン）誘導体
JP2005528431A (ja) * 2002-05-31 2005-09-22 ハー・ルンドベック・アクチエゼルスカベット アルツハイマー病を治療するためのｎｍｄａ−アンタゴニスト及びアセチルコリンエステラーゼ阻害剤の組み合わせ物
EP1585520A1 (en) * 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
CN101460156B (zh) * 2006-05-08 2011-06-08 帝国制药株式会社 抗痴呆药的经皮吸收制剂
WO2007146073A2 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja
WO2009005519A1 (en) * 2007-06-29 2009-01-08 Accera, Inc. Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Also Published As

Publication number Publication date
IL239192B (en) 2019-03-31
DOP2015000133A (es) 2015-11-30
EP2931276A1 (en) 2015-10-21
CA2893468A1 (en) 2014-06-19
HUE036280T2 (hu) 2018-06-28
KR20150095681A (ko) 2015-08-21
PE20151026A1 (es) 2015-07-11
MX362886B (es) 2019-02-22
WO2014090929A1 (en) 2014-06-19
AU2013357308B2 (en) 2017-08-31
US20150297585A1 (en) 2015-10-22
US9211288B2 (en) 2015-12-15
PT2931276T (pt) 2018-03-19
MA38253A1 (fr) 2017-02-28
RS56949B1 (sr) 2018-05-31
MA38253B1 (fr) 2017-10-31
BR112015013675B1 (pt) 2022-04-26
ME03029B (me) 2018-10-20
SG11201504483YA (en) 2015-07-30
DK2931276T3 (en) 2018-03-26
SI2931276T1 (en) 2018-05-31
NO2970700T3 (es) 2018-05-26
AU2013357308A1 (en) 2015-06-18
GEP201706739B (en) 2017-09-25
CN104853755A (zh) 2015-08-19
MY171802A (en) 2019-10-30
ZA201504274B (en) 2016-11-30
MX2015007269A (es) 2015-08-12
CA2893468C (en) 2021-01-12
PH12015501302A1 (en) 2016-02-01
AP2015008498A0 (en) 2015-05-31
EP2931276B1 (en) 2018-02-21
GT201500143A (es) 2016-01-22
PH12015501302B1 (en) 2016-02-01
JP2016502990A (ja) 2016-02-01
PL2931276T3 (pl) 2018-06-29
RU2635528C2 (ru) 2017-11-13
AR093939A1 (es) 2015-07-01
IL239192A0 (en) 2015-07-30
KR102171152B1 (ko) 2020-10-29
EA201590932A1 (ru) 2015-10-30
JP6257641B2 (ja) 2018-01-10
ECSP15023182A (es) 2015-12-31
UA114016C2 (xx) 2017-04-10
TN2015000235A1 (en) 2016-10-03
CY1120098T1 (el) 2018-12-12
HRP20180333T1 (hr) 2018-04-06
EA028300B1 (ru) 2017-10-31
CN104853755B (zh) 2017-08-22
BR112015013675A2 (pt) 2017-07-11
RU2015122256A (ru) 2017-01-16
CL2015001615A1 (es) 2015-08-07
ES2663680T3 (es) 2018-04-16
HK1212601A1 (zh) 2016-06-17
LT2931276T (lt) 2018-04-10
NZ708595A (en) 2019-06-28
NI201500078A (es) 2016-02-15
CR20150303A (es) 2016-07-07

Similar Documents

Publication Publication Date Title
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
CL2014001829A1 (es) Compuestos derivados de indolizina; procedimiento de preparación; composiciones farmacéuticas que los contienen y uso en el tratamiento del cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
CL2014002334A1 (es) Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
UY34610A (es) Pirroldicarboxamidas condensadas y su uso como agentes farmacéuticos.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
UY34590A (es) Fenilimidazopirazoles sustituidos y su uso
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
UY34829A (es) Nueva dosificación y formulación
BR112015005562A2 (pt) compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.